Publications
185 publications
Funding
5 grantsView NIH portfolio on RePORTER ↗
Active
4 grants- MPIT32CA009207-48Investigational Cancer Therapeutics Training Program (ICTTP)NCI · 1977–2029 · via NIH RePORTER
- MPIR01CA273224-05Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted TherapyNCI · 2022–2027 · via NIH RePORTER
- PIR01CA251591-05Predicting sensitivity and resistance in RET-driven cancersNCI · 2021–2027 · via NIH RePORTER
Completed grants (1)
- PIR01CA226864-04Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibitionNCI · 2018–2023 · via NIH RePORTER
Media highlights
2 clips
- Zidesamtinib Demonstrates 94% Response Rate In TKI-Naive Patients With Advanced ROS1 -Positive NSCLCThe ASCO Post · September 17, 2026
- ARROS-1: Zidesamtinib Induces Complete Responses In ROS1-Positive, TKI-Naïve NSCLCCancer Therapy Advisor · September 17, 2026